| Dr Hermann Francisco Gonzalez, DO | |
|
3145 Sterling Way, Portsmouth, VA 23703-4538 | |
| (757) 314-7168 | |
| Not Available |
| Full Name | Dr Hermann Francisco Gonzalez |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 3145 Sterling Way, Portsmouth, Virginia |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1356329304 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 0102201630 (Virginia) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Hermann Francisco Gonzalez, DO 3145 Sterling Way, Portsmouth, VA 23703-4538 Ph: (757) 314-7168 | Dr Hermann Francisco Gonzalez, DO 3145 Sterling Way, Portsmouth, VA 23703-4538 Ph: (757) 314-7168 |
News Archive
An eye-opening article from the International Cancer Genome Consortium was published today in the prestigious journal Nature Communications. It lays a foundation for the coming era of research in cancer genomics.
Newly published research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development by CytoDyn Inc., to effectively block the development of graft-versus-host disease (GvHD), a potentially lethal complication of bone marrow stem cell (BMSC) transplantation.
Performed in less than a month, sequencing of the complete genome and subsequent phylogenetic analysis show that the virus present in Guinea forms a clade (variant) that is distinct from strains previously identified in the Democratic Republic of Congo and in Gabon. Epidemiological investigations also linked the laboratory confirmed cases with the initial deaths recorded during the December 2013 outbreak.
The Biotechnology Industry Organization (BIO) today announced the selection of therapeutic workshops to be presented at the Thirteenth Annual BIO CEO & Investor Conference, taking place February 14-15.
Gilead Sciences, Inc. and GlaxoSmithKline today announced a licensing agreement to commercialize Viread® (tenofovir disoproxil fumarate) for the treatment of chronic hepatitis B (HBV) infection in adults in five countries in Asia. The companies' combined commercialization activities will expand access to Viread for the treatment of HBV, once approved, to patients in Asia where the prevalence in most countries is greater than 8 percent.
› Verified 3 days ago
Dr. Derek Matthew Miletich, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-5000 | |
Dr. Edwin Gonzalez, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-8229 Fax: 757-953-8225 | |
Dr. Adrienne Dawn Pettebone, D.O. General Practice Medicare: Medicare Enrolled Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-1043 | |
Dr. Katie Marie Mcauliffe, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 620 John Paul Jones Cir, Naval Medical Center Portsmouth, Portsmouth, VA 23708 Phone: 757-314-0830 | |
Dr. William R Shannon, MD General Practice Medicare: Not Enrolled in Medicare Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-3238 | |
Dr. Raphael Fajardo Guanzon, M.D. General Practice Medicare: Medicare Enrolled Practice Location: 704 London St # A, Portsmouth, VA 23704 Phone: 757-399-0513 | |
Dr. Joel Metzger, M.D. General Practice Medicare: Not Enrolled in Medicare Practice Location: 620 John Paul Jones Cir, Portsmouth, VA 23708 Phone: 757-953-1128 |